The immunology of psoriasis and biologic immunotherapy

Journal of the American Academy of Dermatology

Volumn 49, Issue 2 A, 2003, Pages 44-50

  Mehlis, Stephanie L ^a   Gordon, Kenneth B ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; EFALIZUMAB; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN MONOCLONAL ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; EFFECTOR CELL; IMMUNOMODULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCID MOUSE; SKIN DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0042634230     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(03)01134-4     Document Type: Review

References (48)

1. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999;26:723-33.
2. Bjerke JR, Krogh HK, Matre R. Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol 1978;71: 340-3.
3. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-9.
4. Nickoloff BJ. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc 2000;5:67-73.
5. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 1995;146:580-8.
6. Boehncke WH, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature 1996;379:777.
7. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 1997;109:283-8.
8. Sugai J, Iizuka M, Kawakubo Y, Ozawa A, Ohkido M, Ueyama Y, et al. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 1998;17:85-92.
9. Yamamoto T, Matsuuchi M, Katayama I, Nishioka K. Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J Dermatol Sci 1998;17:8-14.
10. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
11. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-6.
12. Waters CA, Snider CE, Itoh K, Poisson L, Strom TB, Murphy JR, et al. DAB4861L-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann N Y Acad Sci 1991;636:403-5.
13. Wingren AG, Parra E, Varga M, Kalland T, Sjogren HO, Hedlund G, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995;15:235-53.
14. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
15. th Annual Meeting of the American Academy of Dermatology; March 2-7, 2001; Washington, DC.
16. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998;38:938-44.
17. Berridge MJ. Lymphocyte activation in health and disease. Crit Rev Immunol 1997;17:155-78.
18. Trowsdale J, Campbell RD. Complexity in the major histocompatibility complex. Eur J Immunogenet 1992;19:45-55.
19. Aringer M. T lymphocyte activation - an inside overview. Acta Med Austriaca 2002;29:7-13.
20. Hudrisier D, Bongrand P. Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J 2002;16:477-86.
21. Friedl P, Gunzer M. Interaction of T cells with APCs: the serial encounter model. Trends Immunol 2001;22:187-91.
22. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 1991;349:796-9.
23. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-81.
24. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-28.
25. Bonifati C,Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38:241-51.
26. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
27. Cho SG, Park YM, Moon H, Kim KM, Bae SS, Kim GB, et al. Psoria-siform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer. J Korean Med Sci 1998;13:685-8.
28. Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996;107:778-82.
29. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002;138:657-63.
30. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
31. Ellis C, Krueger G, Haney J, Bennett D, Magilavy D. Safety and efficacy of retreatment with alefacept (LFA3TIP) in chronic plaque psoriasis [abstract]. Poster presented at: the 59th Annual Meeting of the American Academy of Dermatology; March 2-7, 2001; Washington, DC.
32. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.
33. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in Psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
34. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-94.
35. Adorini L, Trembleau S. Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. Biochem Soc Trans 1997; 25:625-9.
36. Finkelman FD. Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med 1995;182:279-82.
37. Ekberg H, Backman L, Tufveson G, Tyden G. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. Transplant Proc 1999;31:267-8.
38. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
39. Fukuoka M, Ogino Y, Sato H, Ohta T, Komoriya K, Nishioka K, et al. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol 1998;138:63-70.
40. Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999;79:9-11.
41. Oyama N, Sekimata M, Nihei Y, Iwatsuki K, Homma Y, Kaneko F. Different growth properties in response to epidermal growth factor and interleukin-6 of primary keratinocytes derived from normal and psoriatic lesional skin. J Dermatol Sci 1998;16:120-8.
42. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-47.
43. Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991;39:141-8.
44. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998;111:1053-7.
45. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32.
46. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87.
47. Huang BB, Bonish BK, Chaturvedi V, Qin JZ, Nickoloff BJ. Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. J Invest Dermatol 2001;116:305-12.
48. Reich K, Westphal G, Schulz T, Muller M, Zipprich S, Fuchs T, et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 1999;113:214-20.